New Stock Debut | DUALITYBIO-B Listed on First Day with a 91.33% Opening Surge, Company is an ADC Innovative Drug Developer
DUALITYBIO-B debuted on its first day of listing, opening with a rise of 105%, priced at HKD 195. The share price was set at HKD 94.6, with 17.3323 million shares issued, netting approximately HKD 1.513 billion. The company focuses on the research and development of antibody-drug conjugates (ADC), has two core products, and is conducting multiple clinical trials globally, establishing partnerships with several biopharmaceutical companies, with a total transaction value exceeding USD 6 billion
According to Zhitong Finance APP, DUALITYBIO-B (09606) has officially listed, with an announcement showing a price of HKD 94.6 per share, issuing a total of 17.3323 million shares, with each lot consisting of 100 shares, and the net proceeds amounting to approximately HKD 1.513 billion. As of the time of writing, it has risen by 91.33%, trading at HKD 181, with a transaction volume of HKD 782 million.
Public information shows that DUALITYBIO officially began operations in 2020 and is a global leader in the field of antibody-drug conjugates (ADC). Several ADCs in clinical stages are conducting 7 global clinical trials across over 230 clinical trial centers in 17 countries, with more than 2,000 patients enrolled, 50% of whom are from overseas. The company has two core products developed independently, namely DB-1303/BNT323 (an HER2 ADC candidate targeting HER2 cancers, including endometrial cancer (EC) and breast cancer (BC)) and DB-1311/BNT324 (a B7-H3 ADC candidate targeting B7-H3 cancers, including small cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), and esophageal squamous cell carcinoma (ESCC)).
In addition, the company has five clinical-stage assets that have received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) and the National Medical Products Administration of China. The company's innovative ADC assets have attracted leading biopharmaceutical companies and established several global partnerships, including collaborations with BioNTech, BeiGene, Adcendo, GSK, and Avenzo, with a total transaction value exceeding USD 6 billion
